<DOC>
	<DOCNO>NCT01465867</DOCNO>
	<brief_summary>Serum level isolate anti-thyroperoxidase ( TPOab ) anti-thyreoglobulin ( Tgab ) autoantibodies strongly associate increase risk miscarriage premature delivery euthyroid pregnant woman . Replacement thyroxine ( LT4 ) supplementations euthyroid-Ab positivity pregnancy establish . The development safe effective intervention modulates inappropriate inflammatory response could important component prevention adverse health outcome pregnancy . The anti-oxidant Selenium ( Se ) suppress autoimmune destruction thyrocytes daily dose 200 mcg 100 mcg decrease titer serum TPOAb TgAb also Se-non-deficient patient autoimmune thyroiditis ( AIT ) . The use Se AIT show reduce incidence postpartum thyroiditis hypothyroidism . Women recurrent pregnancy loss lower Se level Se deficiency implicate pathogenesis AIT impairment T/B cell-mediated immunity . The purpose present study perform establish effect Se supplementation euthyroid woman AIT ( pregnant embryo transfer expect within 60 day ) Ab trend , thyroid function structure , implantation rate , pregnancy rate , pregnancy outcome number obstetrical , fetal neonatal complication .</brief_summary>
	<brief_title>Selenium Supplementation Pregnancy</brief_title>
	<detailed_description>Adverse outcome , postpartum thyroid dysfunction permanent hypothyroidism associate isolated TPOab positivity euthyroid pregnant woman . In area severe selenium deficiency high incidence thyroiditis due decrease activity selenium-dependent glutathione peroxidase activity within thyroid cell . Selenium-dependent enzyme also several modify effect immune system . Therefore , even mild selenium deficiency may contribute development maintenance autoimmune thyroid disease . Selenium substitution exert anti-inflammatory anti-oxidant activity . Se could represent important supplementation euthyroid woman AIT order improve thyroid function structure prevent obstetrical adverse event relate autoimmune disease reactive oxygen specie , recurrent miscarriage pre-eclampsia . The aim study document effect Selenium Supplementation without L-thyroxine ( LT4 ) euthyroid woman AIT , pregnancy . This protocol evaluate trend TPOab Tgab , selenium concentration , thyroid volume echogenicity , nodule formation number adverse effect affect mother ( pregnancy ) , fetus , infant heath service , need elucidate nature emerge association . The study also aim assess impact Selenium Supplementation implantation rate pregnancy rate woman transfer plan within next 60 day . This design phase IV study treatment cohort size pregnant woman woman embryo transfer expect within 60 day TSH value normal range ( 0.4-2.5 mUI/mL ) Tgab and/or TPOab positivity . We perform two randomization arm : Randomization arm A include woman LT4 replacement-free take Selenium Placebo Randomization arm B include woman already LT4 replacement take Selenium Placebo . Patients include Randomization A move Randomization B , TSH increase 2.5 mUI/mL pregnancy . Pregnant woman TSH &gt; 2.5 mU/mL time 0 begin ( adjust ) LT4 replacement include Randomization arm B . Accounting 30 % drop , total enrolment 150 patient plan . Patients randomize time 0 ( 10°± 2 week gestation ) . Follow-up visit take place week 14 ± 2 , 24 ± 2 , 32 ± 2 , 36 ± 2 week , month 3° 6° labour . An optional visit could do 12 month labor . Plasma serum monitor thyroid hormone , Tgab , TPOab , Se concentration , Selenoproteins cytokine , thyroid US , SF12 questionnaire make follow-up visit . At visit 3 ( 24 ± 2 week ) patient optionally OGTT ) . Gestational , obstetrical , maternal , fetal , infant anamnestic data take , follow visit labour . The long-term objective identify safe easily administer supplementation improve : 1. implantation pregnancy rate infertile woman Tgab and/or TPOab positives 2. maternal fetal complication pregnant euthyroid woman Tgab and/or TPOab positive .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Thyroiditis</mesh_term>
	<mesh_term>Thyroiditis , Autoimmune</mesh_term>
	<mesh_term>Hashimoto Disease</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>pregnant woman 10°± 2 week gestation woman embryo transfer expect within 60 day euthyroid woman ( 0.4 μIU/ml &lt; TSH &lt; 2.5 μIU/ml ) , positive TPOab and/or TgAb , assume LT4 replacement euthyroid woman ( 0.4 μIU/ml &lt; TSH &lt; 2.5 μIU/ml ) , positive TPOab and/or TgAb LT4 replacement ( maintain TSH within control range ) . woman TSH &gt; 2.5 μIU/ml positive TPOab and/or TgAb , assume LT4 replacement ( require begin LT4 replacement ) woman TSH &gt; 2.5 μIU/ml positive TPOab and/or TgAb , LT4 replacement ( require adjustment LT4 replacement ) use dietary supplement contain selenium previous 4 month ; use antidepressive/psychotic drug , amiodarone , propanolol , lithium , cytokine ; history hyperthyroidism positive antithyrotropin ab ; previous partial total thyroidectomy ; know fetal anomaly ; know infection ( PID , HIV , HCV ) mola hydatidoses ; chronic renal failure ; uncontrolled hypertension ; uterine malformation ; history medical metabolic complication heart disease diabetes ; previous embryo transfer fail within last 3 month ; miscarriage within last 3 month ; gestational diabetes previous pregnancy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Selenium</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Auto-immune thyroiditis</keyword>
	<keyword>Post-partum thyroiditis</keyword>
	<keyword>Miscarriage</keyword>
	<keyword>Pre-eclampsia</keyword>
	<keyword>Implantation Pregnancy rate</keyword>
	<keyword>Infertility</keyword>
</DOC>